Impact on ventricular arrhythmic burden of SGLT2 inhibitors in patients with chronic heart failure evaluated with cardiac implantable electronic device monitoring.
J Cardiol
; 2024 Sep 13.
Article
em En
| MEDLINE
| ID: mdl-39278346
ABSTRACT
BACKGROUND:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have revolutionized the therapeutic scenario of heart failure, demonstrating favorable effects on mortality and quality of life. Previous studies have yielded conflicting data regarding the effects on ventricular arrhythmias.METHODS:
A prospective observational study was conducted to investigate the anti-arrhythmic properties of SGLT2 inhibitors evaluating the intra-patient difference in major adverse arrhythmic cardiac events (MAACE) over a six-month period in patients with chronic heart failure who were undergoing continuous monitoring using a cardiac implantable electronic device.RESULTS:
From January 2022 to January 2023, 82 patients [median age 63â¯years (IQR 15), male 87â¯%] were enrolled in the study, with a median follow-up of 28â¯weeks (IQR 5). The rate of MAACE at baseline was 11â¯%, without relevant differences in the follow up in terms of major and minor arrhythmic events. In patients with an arrhythmic phenotype at baseline, a mild but non statistically significant reduction of MAACE (from 36â¯% to 28â¯%, pâ¯=â¯0.727) was observed and a significant decrease of non-sustained ventricular tachycardia (from 68â¯% to 32â¯%, pâ¯=â¯0.022).CONCLUSIONS:
Our findings suggest potential anti-arrhythmic properties of SGLT2 inhibitors, evident in patients with arrhythmic events before the initiation of the drug.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
J Cardiol
Ano de publicação:
2024
Tipo de documento:
Article